Alvotech
NASDAQ:ALVODrug Manufacturers - Specialty & Generic
-$0.04 today
- Market cap
- $1.62B
- Beta
- 0.21
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.24
Volume 1.56M
Average 0.65M
ALVO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
AlvotechNASDAQ: ALVO
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $24.51M fell 35.8% year over year, behind the +6.8% change in trailing-twelve-month research & development. Sequentially, it fell 38.2% from the prior quarter. Over 3 fiscal years it compounded at +0.7% a year.
Context
- Research & development amounted to 31.4% of revenue in FY2025, down 3.6 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -35.8% toward the trailing-twelve-month pace of +6.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 184.19M USD
- Year-over-year change
- +7.5%
- 4-year CAGR
- -0.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 184.19M | +7.5% |
| FY2024 | 2024-12-31 | 171.31M | -18.7% |
| FY2023 | 2023-12-31 | 210.83M | +16.7% |
| FY2022 | 2022-12-31 | 180.62M | -5.4% |
| FY2021 | 2021-12-31 | 191.01M | — |
Research & Development vs competitors
How ALVO compares with its peers on the latest reported figures
- ALVO's LTM Mar 2026 research & development of $170.53M is the 7th highest of the 11 companies compared; the peer median is $267.33M.
- Its year-over-year change of +6.8% is the 6th highest of 10, against a peer median of +16.9%.
- Research & development amounts to 30.5% of revenue for ALVO, versus a peer median of 7.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $7.64B | +19.3% | +16.3% | 20.0% | |
| LTM Jun 2026 | $6.46B | +16.9% | +24.2% | 41.6% | |
| LTM Jun 2026 | $1.95B | -19.9% | -9.0% | 19.6% | |
| LTM Jun 2026 | $995M | -0.7% | +6.5% | 5.7% | |
| LTM Sep 2026 | $357M | -11.9% | -8.1% | 5.9% | |
| LTM Jun 2026 | $177.66M | -15.0% | -3.7% | 5.7% | |
| LTM Mar 2026 | $170.53M | +6.8% | +0.7% | 30.5% | |
| LTM Mar 2026 | $92.49M | +20.2% | +4.7% | 12.8% | |
| LTM Mar 2026 | $15.36M | +17.2% | +61.5% | 5.7% | |
| LTM Mar 2026 | $8.48M | +125.2% | +24.8% | 9.8% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ALVO) | $267.33M | +16.9% | +6.5% | 7.8% | |
Competitors are the stored peer set for ALVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 36.77M | 83.03M | 91.43M | 489.68M | 586.32M |
| Cost of Revenue | 0 | 64.1M | 160.86M | 185.31M | 235.56M |
| Gross Profit | 36.77M | 18.93M | (69.42M) | 304.37M | 350.76M |
| Gross Margin | 100.0% | 22.8% | -75.9% | 62.2% | 59.8% |
| Research & Development | 191.01M | 180.62M | 210.83M | 171.31M | 184.19M |
| Selling, General & Admin | 84.13M | 186.74M | 73.04M | 61.45M | 90.95M |
| Operating Expenses | 272.23M | 365.38M | 285.44M | 234.73M | 272.56M |
| Depreciation & Amortization | 18.2M | 20.41M | 24.21M | 31.3M | 37.85M |
| EBITDA | (18.03M) | (439.8M) | (493.67M) | (32.28M) | 323.39M |
| EBITDA Margin | -49.0% | -529.7% | -539.9% | -6.6% | 55.2% |
| Operating Income | (235.46M) | (346.44M) | (354.86M) | 69.64M | 78.21M |
| Operating Margin | -640.3% | -417.3% | -388.1% | 14.2% | 13.3% |
| Interest Income | 19K | 912K | 4.82M | 4.62M | 198.49M |
| Interest Expense | 112.97M | 91.44M | 134.82M | 157.6M | 149.19M |
| Other Income / Expenses | 86.26M | (205.21M) | (296.19M) | (287.21M) | 58.14M |
| Income Before Tax | (149.2M) | (551.65M) | (651.05M) | (217.56M) | 136.35M |
| Pre-Tax Margin | -405.7% | -664.4% | -712.0% | -44.4% | 23.3% |
| Income Tax Expense | (47.69M) | (38.07M) | (99.32M) | 14.3M | 108.43M |
| Net Income | (101.5M) | (513.58M) | (551.73M) | (231.86M) | 27.92M |
| Net Margin | -276.0% | -618.6% | -603.4% | -47.3% | 4.8% |
| EPS (Basic) | (3.25) | (2.60) | (2.43) | (0.87) | 0.10 |
| EPS (Diluted) | (3.25) | (2.60) | (2.43) | (0.87) | 0.10 |
| Weighted Avg Shares | 31.25M | 197.72M | 227.26M | 267.92M | 279.19M |
| Weighted Avg Shares (Diluted) | 31.25M | 197.72M | 227.26M | 267.92M | 279.19M |
Alvotech
NASDAQ:ALVO
Intrinsic Alpha fair value
Locked
Current Price
$4.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.